For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
The closing price of Arcus Biosciences Inc (NYSE: RCUS) was $21.91 for the day, up 1.76% from the previous closing price of $21.53. In other words, the price has increased by $1.76 from its previous closing price. On the day, 3.75 million shares were traded. RCUS stock price reached its highest trading level at $22.0 during the session, while it also had its lowest trading level at $20.82.
Ratios:
Our analysis of RCUS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In the most recent recommendation for the company, H.C. Wainwright on February 26, 2025, Upgraded its rating to Buy and sets its target price to $24 from $18 previously.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.
On October 08, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $29.Wells Fargo initiated its Overweight rating on October 08, 2024, with a $29 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 16 ’25 when Richard Markus bought 10,000 shares for $21.90 per share.
Carolyn Tang bought 15,000 shares of RCUS for $328,500 on Dec 16 ’25. On Dec 16 ’25, another insider, Alexander Azoy, who serves as the Officer of the company, bought 5,000 shares for $21.90 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 2710892288 and an Enterprise Value of 1666700160. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.30 while its Price-to-Book (P/B) ratio in mrq is 5.38. Its current Enterprise Value per Revenue stands at 6.945 whereas that against EBITDA is -4.566.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.79, which has changed by 0.33893037 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $26.40, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is 7.98%, while the 200-Day Moving Average is calculated to be 79.38%.
Shares Statistics:
RCUS traded an average of 1.66M shares per day over the past three months and 2445790 shares per day over the past ten days. A total of 107.10M shares are outstanding, with a floating share count of 81.21M. Insiders hold about 34.37% of the company’s shares, while institutions hold 53.16% stake in the company. Shares short for RCUS as of 1764288000 were 9085675 with a Short Ratio of 5.48, compared to 1761868800 on 8344964. Therefore, it implies a Short% of Shares Outstanding of 9085675 and a Short% of Float of 10.459999999999999.
Earnings Estimates
A detailed examination of Arcus Biosciences Inc (RCUS) is currently in progress, with 4.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$1.01, with high estimates of -$0.79 and low estimates of -$1.18.
Analysts are recommending an EPS of between -$3.48 and -$3.52 for the fiscal current year, implying an average EPS of -$3.5. EPS for the following year is -$3.87, with 4.0 analysts recommending between -$3.54 and -$4.13.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $40M to a low estimate of $16M. As of. The current estimate, Arcus Biosciences Inc’s year-ago sales were $36MFor the next quarter, 8 analysts are estimating revenue of $30.28M. There is a high estimate of $55M for the next quarter, whereas the lowest estimate is $16M.
A total of 10 analysts have provided revenue estimates for RCUS’s current fiscal year. The highest revenue estimate was $254M, while the lowest revenue estimate was $229M, resulting in an average revenue estimate of $237.5M. In the same quarter a year ago, actual revenue was $258MBased on 10 analysts’ estimates, the company’s revenue will be $118.8M in the next fiscal year. The high estimate is $225M and the low estimate is $37M.
